## **Core Concept**
Gastrointestinal stromal tumors (GISTs) are a type of tumor that occurs in the digestive tract, most commonly in the stomach or small intestine. They are known to arise from the interstitial cells of Cajal or their precursors. The molecular pathogenesis of GISTs is primarily associated with mutations in specific proto-oncogenes.

## **Why the Correct Answer is Right**
The correct answer, **KIT**, is a proto-oncogene that encodes a receptor tyrosine kinase. In GISTs, mutations in the **KIT** gene lead to the constitutive activation of the KIT protein, which promotes cell proliferation and survival without the need for its ligand. This aberrant activation is a key driver of tumorigenesis in GISTs. Another gene, **PDGFRA**, is also implicated in GISTs, but **KIT** mutations are more common.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While **KRAS** is a well-known proto-oncogene involved in various cancers, it is not primarily associated with GISTs. **KRAS** mutations are more commonly found in colorectal, lung, and pancreatic cancers.
- **Option B:** **FMS** (or **CSF1R**) is a proto-oncogene that can be involved in certain types of cancer, but it is not specifically associated with GISTs.
- **Option D:** **BCL2** is a proto-oncogene that regulates apoptosis, or programmed cell death. While alterations in **BCL2** family members can contribute to oncogenesis in various cancers, **BCL2** itself is not directly implicated in the pathogenesis of GISTs.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that GISTs are often resistant to conventional chemotherapy but can be effectively treated with tyrosine kinase inhibitors (TKIs) that target the KIT and/or PDGFRA pathways. Imatinib, a TKI, is a first-line treatment for unresectable or metastatic GISTs, reflecting the critical role of **KIT** and **PDGFRA** in these tumors.

## **Correct Answer:** C. KIT